Opinion|Videos|July 8, 2024
Outcomes from NATALEE and MonarchE
Dr. Dempsey discusses key results from the NATALEE and MonarchE trials.
Advertisement
Video content above is prompted by the following:
- (Dr. O’Shaughnessy) How have the MonarchE and NATALEE trials contribute to our understanding of the optimal duration of adjuvant endocrine therapy?
- How might the difference in adjuvant therapy duration between ribociclib and abemaciclib influence discussions around risk-benefit assessments with patients considering CDK4/6i?
- (Dr. Rugo)How does incorporating CDK4/6i earlier in treatment impact how the relapsed/refractory setting is managed?
- Please include a discussion of ribociclib’s MAINTAIN trial. Discuss your thoughts on continued use of CDK4/6i in the R/R setting, as well as sequencing considerations.
- Please also include a discussion of capivasertib as a newly approved option based on the CAPItello-291 trial.
Advertisement
Related to this article
Legal and clinical experts examined the US medical aid in dying framework, its limits, and ethical debates.
Myeloma faculty from UT Southwestern Medical Center and pharmacy leaders from Texas Oncology discussed how teclistamab- and talquetamab-based regimens are reshaping early relapse in multiple myeloma. Observation-stay economics and physician comfort, not clinical data, are slowing delivery closer to home.
Speakers at IDWeek 2026 urged shifting global health partnerships from donor-recipient models to shared, locally led ownership as funding contracts.
Off-the-shelf CTX110 allogeneic CD19 CAR T shows responses in relapsed/refractory B-cell lymphoma, with manageable cytokine release syndrome.
Declining serum GFAP during MS treatment was tied to lower PIRA risk, supporting its use as a biomarker for treatment response.
David G. Mitchell, PharmD, MBA, CSP, FCPhA, of UC Davis Health, explains how AI-assisted prior authorizations have reduced denials and staff time without replacing pharmacist judgment.
Nearly half of working-age adults were inadequately insured in 2026, and half went without needed care due to cost, a Commonwealth Fund survey found.
Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.
Advertisement
Advertisement
Trending on AJMC
1
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
2
Extension Studies in TPIP Show Promise in PAH, PH-ILD
3
Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease
4
Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD
5